Nursing Pharmacology:  Antiviral Drugs

• Antiviral Drugs

  • Acyclovir and Related Drugs continued:

    • Drug Resistance

      • Acyclovir and its derivatives represent first-line drugs both for HSV infection prophylaxis as well as for treatment.⁴ 

        • These agents are "prodrugs" and require several phosphorylation steps to form the active compound.

        • The first phosphorylation step is dependent on a virus-encoded thymidine kinase (TK).

        • Host cellular GMP kinase and nucleoside diphosphate kinase catalyze the two additional phosphorylation steps.

      • Long-term administration of acyclovir and related agents can lead to the development of resistance, particularly in immunocompromised patients. ⁴ 

        • The likelihood of the development of acyclovir-resistance in herpes simplex virus isolates (HSV isolates) is quite different between immunocompetent and immunocompromised individuals.

        • The most important factor may be that host responses are impaired and less pathogenic viral strains that normally would not survive in the context of a normal host response may continue to replicate.

          • The prevalence of acyclovir resistance in HSV in immunocompetent patients ranges from about 0.3% to 0.7%.

          • By contrast, the prevalence of HSV infections with diminished acyclovir susceptibility in immunocompromised patients is about 10 times higher, 3.5% to about 10%.

      • Taking into account the mechanism of acyclovir-antiviral action, viral mutations that confer resistance to acyclovir have been described.

      • Another mutation sites that confers resistance is associated with the UL30 gene which codes for the DNA polymerase enzyme.⁴  

        • HSV depends on a functional DNA polymerase to replicate; whereas, an intact viral thymidine kinase may be dispensable in some mammalian tissues.

          • Accordingly, a viable acyclovir-resistant virus is more likely found as a result of a mutation in the UL23 gene compared to UL30 gene mutations.

          • Several phenotypes for acyclovir-resistance thymidine kinase (TK) mutants have been described.

            • These include TK-negative mutants which lack thymidine kinase catalytic activity, TK-low-producer mutants which results in decreased enzymatic activity nad TK-altered isolates show substrate-specific mutations in that they phosphorylate thymidine but not acyclovir.

            • Most (95%) of acyclovir-resistant HSV clinical isolates are either thymidine kinase TK-negative or TK-low-producer mutants.⁴ 

  • Acyclic Nucleotide Phosphonates, e.g. Cidofovir (Vistide)

    • The drugs considered to this point are "classical" acyclic nucleoside analogues.

      • Examples of these drugs include acyclovir, ganciclovir and penciclovir.

        • Furthermore, other agents not yet discussed are similar in requiring an initial phosphorylation step.

          • Examples of these drugs include dideoxynucleoside analogues such as zidovudine (AZT) and lamivudine (3TC).

            • Therefore, in cells in which the initial nucleoside kinase exhibits reduced activity or is even not present the nucleoside analogues are inactive.

    • By contrast, another class of drugs are phosphonate derivatives, the acyclic nucleoside phosphonate's or ANPs.

      • ANPs are converted by nucleotide kinase (GMP kinase or AMP kinase) to a monophosphate form, an analog of diphosphate and then to the triphosphate analog by a nucleoside diphosphate kinase.

        • The active form is represented by the triphosphate (ANPpp) analogues.

        • Cidofovir (Vistide) is one example.

      • Cidofovir (Vistide) inhibits viral DNA synthesis.

        • This inhibition occurs by terminating viral DNA chain elongation.⁶

        • As cidofovir is a phosphonate, phosphorylation proceeds only by cellular, not viral enzymes.¹ 

          • Accordingly, cidofovir can inhibit acyclovir-resistant thymidine kinase (TK) or thymidine kinase-modified herpes simplex virus (HSV) or varicella-zoster virus (VZV) strains.¹ 

          • Cidofovir is also effective in some foscarnet-resistant CMV isolates.

            • Cidofovir in combination with ganciclovir or foscarnet inhibits CMV replication in a synergistic manner.¹

          • The molecular target for cidofovir is the viral DNA-dependent DNA polymerase.⁶

            • For tenofovir and adefovir the molecular target in the human immunodeficiency virus (HIV) or hepatitis B is the virus RNA-dependent DNA polymerase (reverse transcriptase)⁶

      • Clinical Case:  Intralesion Cidofovir Treatment of Acyclovir-Resistant Herpes Simplex Virus⁷

        An example of treating acyclovir-resistant HSV with cidofovir is noted in the following clinical case.7  In this case a young HIV-positive male with a history of recurrent genital HSV infection presented with a left-sided nasal lesion. Biopsy specimens characterized extensive granulation tissue and noted that an "indurated, ulcerated plaque recurred and progressed despite surgical removal and corticosteroid injections." 15 months later the nasal lesion had extended to the other nares. Biopsy and pathologic examination revealed HSV changes with significant granulation but absent evidence of T-cell lymphoma or infection. On an outpatient basis the patient had been treated on multiple occasions with oral acyclovir for genital herpes simplex infections without nasal lesion improvement. The mass recurred again despite subsequent pharmacological treatment with IV acyclovir and a partial rhinectomy. The patient was then treated several times with IV acyclovir, vancomycin, along with further surgical debridement. Biopsies of the lesion both confirmed HSV infection and indicated clinical acyclovir resistance.7   This time the patient began receiving IV cidofovir and experienced total lesion clearance after about six weeks of treatment. Upon therapy discontinuation, however, the lesion recurred rapidly an extended towards the lower eyelid. IV cidofovir treatment was restarted. However, the notion of long-term use of IV cidofovir was considered problematic given the risk of renal toxicity. Accordingly, other treatment options were considered. After IV cidofovir had been initiated and only limited lesion improvement noted, the patient began receiving intralesional (IL) cidofovir. Such intralesional injections have been performed in other settings and described in the primary literature. Following intralesional cidofovir treatment, the lesion exhibited substantial improvement.7   "Progression of patient's herpes simplex virus lesion. A, Initial lesion after debridement. B, Recurrence of lesion after treatment with intravenous cidofovir. C. Progression of lesion after initiation of intralesional cidofir. Skin lesion after final treatment with intralesional cidofovir."7 The reader is directed to this case study for more detail.7  Castelo-Soccio L Bernardin R Stern J Goldstein SA Kovarik C Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus with Intralesional Cidofovir.  Arch Dermatol 146(2):  124-126, February 2010. (complete reference) NIH Public Access Author Manuscript:  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874880/

References

Acosta EP Flexner C Antiviral Agents (Nonretroviral) Chapter 58 in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011. Baden LR Dolin R, Chapter 178, Antiviral Chemotherapy, Excluding Antiretroviral Drugs, in Harrison's Online   (Dan L. Longo, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 18th edition, The McGraw-Hill Companies, Inc. 2012. Safrin S Antiviral Agents, Chapter 49 in Basic & Clinical Pharmacology, 12 e (Katzung BG Masters SB Trevor AJ) The McGraw-Hill Companies, 2012 (on-line edition) Piret J Boivin G Minireview:  Resistance of Herpes Simplex Viruses to Nucleoside Analogues:  Mechanisms, Prevalence, and Management. Antimicrobial Agents and Chemotherapy, 55(2):  p. 459-472, Feb. 2011. Gilbert C Bestman-Smith J Goivin G Resistance of herpesviruses to antiviral drugs:  clinical impacts and molecular mechanisms.  Drug Resistance Updates 5:  88-114, 2002. De Clercq E Holy A Acyclic Nucleoside Phosphonates:  A Key Class of Antiviral Drugs Nature Reviews:  Drug Discovery 4: 928-940, 2005. http://www.nature.com/nrd/journal/v4/n11/fig_tab/nrd1877_F1.html Castelo-Soccio L Bernardin R Stern J Goldstein SA Kovarik C Successful Treatment of Acyclovir-Resistant Herpes Simplex Virus with Intralesional Cidofovir.  Arch Dermatol 146(2):  124-126, February 2010. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874880/

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.